HB4317, titled the Pharmacy Benefit Manager Reform Act of 2025, is a broad federal prescription drug pricing and transparency bill focused on Medicare Part D, employer-sponsored health plans, and Medicaid. For Medicare Part D, it would require prescription drug plan sponsors to accept any pharmacy willing to meet standard contract terms, direct the Secretary of Health and Human Services to define what counts as “reasonable and relevant” contract terms, create a pharmacy complaint process, and authorize enforcement actions and penalties for noncompliance. It also adds special reporting for “essential retail pharmacies” in underserved or low-competition areas and requires CMS to publish lists and recurring reports on reimbursement, participation, and cost-sharing trends.
The bill also imposes extensive PBM transparency and accountability requirements across Medicare Part D, Medicare Advantage Part D plans, employer health plans, and Medicaid. It would require PBMs and related entities to report detailed claims-level and aggregate data on drug spending, rebates, fees, remuneration, formulary placement, affiliated pharmacies, and broker/consultant compensation; disclose manufacturer agreements tied to formulary or utilization decisions; and permit audits by plan sponsors. In Medicaid, it would require pass-through pricing for covered outpatient drugs, limit PBM compensation to ingredient cost plus fair dispensing and administrative fees, and prohibit spread pricing for federal matching purposes. The bill further directs studies and reports by GAO, MedPAC, CMS, and HHS OIG, and includes significant appropriations to carry out the new oversight and reporting systems.
If enacted, HB4317 would amend the Social Security Act, the Public Health Service Act, the Employee Retirement Income Security Act, and the Internal Revenue Code to create new federal standards governing pharmacy benefit managers and prescription drug plan contracting. It would expand federal oversight of PBM practices, require new disclosures and standardized reporting, establish enforcement mechanisms and civil monetary penalties, and alter how Medicare Part D, MA-PD, employer health plans, and Medicaid plans contract with PBMs and pharmacies. The bill would also affect pharmacies, PBMs, health plans, employers, manufacturers, brokers, and consultants by imposing new compliance, audit, and transparency obligations, while changing Medicaid reimbursement rules and limiting spread pricing.
Based on the bill’s sponsors and the absence of recorded committee debate or votes in the provided materials, the bill appears to have been introduced as a bipartisan PBM reform measure with strong policy support from lawmakers concerned about drug costs, pharmacy access, and market transparency. The sponsor list includes members from both parties, suggesting an effort to frame the bill as a cross-party response to PBM practices. No formal vote history or transcript record is provided here, so there is no documented opposition or support beyond the bill’s bipartisan introduction and its referral for committee consideration.
The main points of contention likely center on the bill’s extensive regulation of PBMs and affiliated entities, especially the limits on remuneration, the disclosure of rebate and pricing information, and the restrictions on spread pricing in Medicaid. PBMs and potentially some plan sponsors may object to the reporting burden, audit rights, anti-retaliation provisions, and the requirement to disgorge certain remuneration, while pharmacies and consumer advocates are likely to support the access and transparency provisions. Another likely area of dispute is the treatment of affiliated pharmacies and manufacturer-linked arrangements, since the bill explicitly targets incentives that may steer utilization toward owned or preferred channels. The Medicaid pass-through pricing and 340B-related provisions may also draw scrutiny from states, managed care entities, and drug supply chain participants because they alter payment structures and reporting obligations.